MannKind Receives $1 Million Milestone From RLS
January 03 2017 - 9:00AM
MannKind Corporation (NASDAQ:MNKD)
(TASE:MNKD)
today confirmed that following
the completion of initial formulation studies
it received a $1 million milestone payment from Receptor
Life Sciences, Inc. (RLS) on Friday, December 30, 2016.
This milestone payment is part of a previously announced
collaboration and license agreement between the company and
RLS.
Matthew J. Pfeffer, Chief Executive Officer of
MannKind, commented, “The results of these studies have further
validated the versatility of our formulation technology. We
are pleased with the progress to date and look forward to the next
phase of product development in our collaboration with
RLS.”
About MannKind
CorporationMannKind Corporation (NASDAQ:MNKD) (TASE:MNKD)
focuses on the discovery and development of therapeutic products
for patients with diseases such as diabetes. MannKind
maintains a website at http://www.mannkindcorp.com to which
MannKind regularly posts copies of its press releases as well as
additional information about MannKind. Interested persons can
subscribe on the MannKind website to e-mail alerts that are sent
automatically when MannKind issues press releases, files its
reports with the Securities and Exchange Commission or posts
certain other information to the website.
About Receptor Life Sciences,
Inc.Receptor Life Sciences, Inc. is a pharmaceutical
development company based in Seattle, Washington. Receptor is
quietly laying the foundation for groundbreaking new products in
the specialty pharmaceutical market.
Company Contact:
Rose Alinaya
SVP Finance
661-775-5300
ralinaya@mannkindcorp.com
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Mar 2024 to Apr 2024
MannKind (NASDAQ:MNKD)
Historical Stock Chart
From Apr 2023 to Apr 2024